$93.81−5.56 (−5.60%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Spyre Therapeutics (SYRE) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
15 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 95% below its peak (through FY23), net margin −38238.1%. Worth your attention in FY25: Share count (+2349.6%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲25.4%
−155.2
FY21→FY25CAGR —
Free cash flow ($M)—
—
no FY25 valueCAGR —
What the receipts whisper · what a headline number hides
Share count
+2349.6%
2.6mn → 64.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level Gross Operating Net
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 886.0 | 2,329.0 | 18,739.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | —A | —A | 18,739.0 | — | — |
Research & development | 259,721.0 | 171,653.0 | 162,790.0 | 219,692.0 | 58,579.0 | 57,069.0 | ▲5.4% | +31.7% |
Selling, general & admin | 60,450.0 | 47,909.0 | 45,776.0 | 39,946.0 | 28,531.0 | 27,319.0 | ▲4.7% | +15.1% |
Total operating expenses | 250,171.0 | 209,562.0 | 208,566.0 | 243,189.0 | 87,110.0 | 84,388.0 | ▲0.5% | +25.5% |
Operating incomefeeds ROC rank | −250,171.0 | −209,562.0 | −208,566.0 | −242,303.0 | −84,781.0 | −65,649.0 | ▼0.5% | — |
Other income, net | −13,685.0 | 54,344.0 | 599.0 | −96,513.0 | 830.0 | −11.0 | — | — |
Pretax income | −263,856.0 | −155,218.0 | −207,967.0 | −338,816.0 | −83,951.0 | −65,660.0 | ▲25.4% | — |
Income tax | — | −15.0 | 51.0 | −26.0 | −136.0 | 141.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −263,856.0 | −155,203.0 | −208,018.0 | −338,790.0 | −83,815.0 | −65,801.0 | ▲25.4% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | —B | —B | —B | —B | —B | —B | — | — |
Diluted shares (mn) | 0.00 | 64.42 | 0.00 | 7.34 | 0.00 | 2.63 | — | +122.5% |
| Margins | ||||||||
Gross margin | — | — | — | —A | —A | 100.0% | — | — |
Operating margin | — | — | — | −27348.0% | −3640.2% | −350.3% | — | — |
Net margin | — | — | — | −38238.1% | −3598.8% | −351.1% | — | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.B Withheld by our checks.
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

